Table 3.
Cox Regression: Factors Associated With Successful Cyclophosphamide Therapy
| Characteristic Name | Variable | Crude Hazard Ratio (HR), Control of Inflammation (inactive), (95% Confidence Interval (CI) | Adjusted HR, Control of Inflammation (inactive), (95% CI) | Crude HR, Corticosteroid-sparing success (≤10 mg prednisone), (95% CI) | Adjusted HR, Corticosteroid-sparing success (≤10 mg prednisone), (95% CI) |
|---|---|---|---|---|---|
| Sex | Male | 1.46 (1.05 - 2.03) | 1.28 (0.88 - 1.86) | 1.33 (0.92 - 1.92) | 1.17 (0.77 - 1.78) |
| Race | White | 1.00 | 1.00 | 1.00 | 1.00 |
| Black | 0.64 (0.36 - 1.14) | 0.65 (0.38 - 1.12) | 0.38 (0.20 - 0.71) | 0.38 (0.19 - 0.76) | |
| Other | 0.61 (0.31 - 1.20) | 0.70 (0.34 - 1.41) | 0.57 (0.26 - 1.21) | 0.64 (0.28 - 1.43) | |
| Age | <18 years | 6.75 (3.89 - 11.72) | 3.17 (0.27 - 37.95) | 37.25 (17.91 - 77.46) | 5.95 (0.71 - 50.19) |
| 18-39 years | 1.00 | 1.00 | 1.00 | 1.00 | |
| 40-54 years | 1.25 (0.72 - 2.15) | 1.13 (0.57 - 2.26) | 2.09 (1.11 - 3.94) | 2.28 (1.07 - 4.86) | |
| 55-64 years | 1.08 (0.58 - 2.00) | 0.92 (0.42 - 2.01) | 2.08 (1.08 - 3.99) | 2.32 (1.05 - 5.17) | |
| 65 years or more | 0.93 (0.58 - 1.50) | 0.85 (0.44 - 1.65) | 2.05 (1.15 - 3.64) | 2.35 (1.11 - 4.99) | |
| Type of inflammation | Mucous Membrane Pemphigoid | 1.00 | 1.00 | 1.00 | 1.00 |
| Uveitis | 1.08 (0.71 - 1.64) | 1.07 (0.59 - 1.93) | 0.96 (0.60 - 1.54) | 1.49 (0.79 - 2.79) | |
| Scleritis | 0.97 (0.64 - 1.48) | 1.09 (0.70 - 1.69) | 0.71 (0.46 - 1.10) | 0.88 (0.56 - 1.37) | |
| Other | 1.58 (0.84 - 2.96) | 1.39 (0.67 - 2.86) | 1.25 (0.57 - 2.73) | 1.46 (0.64 - 3.35) | |
| Previous Cyclophosphamide | Yes | 0.82 (0.41 - 1.64) | 1.17 (0.50 - 2.73) | 1.15 (0.57 - 2.30) | 1.31 (0.56 - 3.06) |
| Antimetabolite(s) prior to treatment | Yes | 0.77 (0.53 - 1.11) | 0.84 (0.53 - 1.34) | 0.98 (0.66 - 1.46) | 0.84 (0.51 - 1.37) |
| Biologic(s) prior to treatment | Yes | 3.53 (0.89 - 13.96) | 4.82 (0.41 - 56.46) | 10.04 (2.59 - 38.87) | 7.52 (0.90 - 62.73) |
| Alkylating agent(s) prior to treatment | Yes | 0.82 (0.52 - 1.29) | 1.42 (0.67 - 3.03) | 0.56 (0.17 - 1.78) | 1.08 (0.43 - 2.71) |
| Route - Oral | Yes | 1.95 (1.18 - 3.20) | 1.55 (0.82 - 2.94) | 1.27 (0.76 - 2.14) | 0.90 (0.46 - 1.75) |
| Dosage, mg | ≤75 | 1.00 | 1.00 | 1.00 | 1.00 |
| 75 < Dose ≤ 100 | 1.31 (0.73 - 2.37) | 1.05 (0.57 - 1.95) | 1.12 (0.62 - 2.03) | 1.26 (0.67 - 2.36) | |
| 100< Dose ≤ 150 | 2.14 (1.33 - 3.45) | 1.86 (1.08 - 3.20) | 1.67 (1.00 - 2.77) | 1.68 (0.93 - 3.04) | |
| Dose>150 | 1.71 (1.04 - 2.82) | 1.63 (0.93 - 2.87) | 0.99 (0.56 - 1.73) | 1.18 (0.61 - 2.26) | |
| Systemic (extraocular) autoimmune disease | Yes | 1.12 (0.76 - 1.64) | 1.36 (0.86 - 2.17) | 1.01 (0.68 - 1.49) | 1.08 (0.67 - 1.76) |